BCL6 Inhibitor Peptide Have Powerful Anti-Lymphoma Activity in Animal Models of Diffuse Large B-Cell Lymphoma and Synergize with Other Anti-Lymphoma Drugs

TY - JOUR

T1 - BCL6 Inhibitor Peptide Have Powerful Anti-Lymphoma Activity in Animal Models of Diffuse Large B-Cell Lymphoma and Synergize with Other Anti-Lymphoma Drugs

AU - Aparo, Santiago

AU - Cerchietti, Leandro

AU - Antun, Ana

AU - Shaknovich, Rita

AU - Melnick, Ari

N1 - The BCL6 oncogenic transcriptional repressor is constitutively expressed in about 60% of Diffuse Large B-cell Lymphomas (DLBCLs). We previously developed a recombinant inhibitor peptide that specifically blocks the ability of BCL6 to mediate transcriptional repression. Based on this peptide, we developed a novel retro-Inverso peptidomimetic inhibitor called BPI (BCL6 Peptidomimetic Inhibitor) that is far more potent and stable than its prototype.

PY - 2006/11/16

Y1 - 2006/11/16

UR - https://www.sciencedirect.com/science/article/pii/S0006497118422677#!

M3 - Article

VL - 108

JO - Blood / American Society of Hematology 48th Annual Meeting

JF - Blood / American Society of Hematology 48th Annual Meeting

ER -